Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology and Metabolic Control in Patients With Type 2 Diabetes Mellitus on Stable Metformin Treatment

NCT02401880 is registered in ClinicalTrials.gov with Profil Institut für Stoffwechselforschung GmbH as lead sponsor.

NCT NCT02401880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02401880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology and Metabolic Control in Patients With Type 2 Diabetes Mellitus on Stable Metformin Treatment
Lead sponsor
Profil Institut für Stoffwechselforschung GmbH
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2015
Completion date
December 31, 2015
Enrollment
89 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus